Production (Stage)
Fresh Tracks Therapeutics, Inc.
FRTX
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 7.94M | 53.00K | 9.00K | 2.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 7.94M | 53.00K | 9.00K | 2.05M |
| Cost of Revenue | 10.00K | 627.00K | 609.00K | 1.94M | 2.61M |
| Gross Profit | -10.00K | 7.32M | -556.00K | -1.93M | -555.00K |
| SG&A Expenses | 1.64M | 5.32M | 1.81M | 2.41M | 4.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.65M | 5.95M | 2.42M | 4.35M | 6.64M |
| Operating Income | -1.65M | 2.00M | -2.36M | -4.34M | -4.59M |
| Income Before Tax | -1.24M | 2.10M | -2.28M | -4.28M | -4.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.24M | 2.10M | -2.28M | -4.28M | -4.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -197.00K | -- | -- | -- |
| Net Income | -1.24M | 1.91M | -2.28M | -4.28M | -4.53M |
| EBIT | -1.65M | 2.00M | -2.36M | -4.34M | -4.59M |
| EBITDA | -1.64M | 2.01M | -2.35M | -4.33M | -4.58M |
| EPS Basic | -0.21 | 0.32 | -0.39 | -1.14 | -1.50 |
| Normalized Basic EPS | -0.13 | 0.19 | -0.24 | -0.71 | -0.94 |
| EPS Diluted | -0.21 | 0.32 | -0.39 | -1.14 | -1.50 |
| Normalized Diluted EPS | -0.13 | 0.19 | -0.24 | -0.71 | -0.94 |
| Average Basic Shares Outstanding | 5.98M | 5.91M | 5.91M | 3.76M | 3.01M |
| Average Diluted Shares Outstanding | 5.98M | 5.91M | 5.91M | 3.76M | 3.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |